Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Insilico Medicine

Tracked across 11 events · 378 articles · First seen Apr 02, 2026 · Last active Sep 10, 2026

Sentiment
47
Attention
6
Events
11
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 75
Business
Impact: Insilico Medicine has entered into a strategic collaboration with Takeda, leveraging its Pharma.AI platform for drug discovery. This agreement could bring Insilico Medicine up to $600 million in milestone payments and royalties, significantly boosting its financial outlook and validating its AI-driven approach.
Jul 02, 2026 · 8 articles
3 60
Business
Impact: Insilico deepens its partnership with CMS, securing up to 1.2 billion RMB in milestones and royalties, reinforcing its AI platform's productivity and out-licensing strategy.
Jul 13, 2026 · 6 articles
3 40
Regulatory
Impact: Insilico received its first FDA Fast Track Designation for ISM6331, validating its AI-driven drug discovery platform and potentially accelerating clinical development. The company's stock rose 1.40% on the news.
Jul 29, 2026 · 7 articles
4 40
Tech
Impact: Insilico Medicine is the developer and provider of the DDD Benchmark, leveraging its proprietary data and validated programs. This launch enhances its reputation as a leader in AI-driven drug discovery and could drive business growth through benchmarking services.
Jul 30, 2026 · 6 articles
2 80
Business
Impact: Central company; inclusion enhances visibility, liquidity, and capital access, likely benefiting its stock.
Jul 20, 2026 · 6 articles
6 80
Tech
Insilico Medicine, a China — Hong Kong-based biotech firm, published findings in Nature Biotechnology showing that its AI-designed drug rentosertib reduced biological age markers in patients with idiopathic pulmonary fibrosis (IPF). The drug, originally developed…
Impact: Developer of rentosertib and publisher of the study; positive results enhance its reputation and prospects in AI drug discovery.
Sep 07, 2026 · 6 articles
4 40
Tech
Insilico Medicine announced on September 9-10, 2026 that it has dosed the first patient with Rentosertib (ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial for idiopathic pulmonary fibrosis (IPF), at United Medical College…
Impact: Insilico Medicine is the central actor, dosing the first patient in the Phase III trial of Rentosertib and reporting strong revenue growth and profitability. The milestone strengthens its AI-driven drug discovery narrative and could positively affect its Hong Kong-listed shares.
Sep 10, 2026 · 6 articles
2 15
Tech
Impact: Named leader in discovery and preclinical AI, potentially boosting its market credibility.
Aug 10, 2026 · 6 articles
2 50
Business
Impact: Signed strategic cooperation agreement with Tigermed, focusing on AI enablement in drug development.
Jul 20, 2026 · 6 articles
2 30
Tech
Impact: Mentioned as an existing customer of Liquid AI, serving as a reference for Liquid AI's capabilities but not directly impacted.
Aug 05, 2026 · 6 articles
6 10
International
Impact: Founder Alex Zhavoronkov praised Chinese open-source models.
Jul 08, 2026 · 315 articles
Hong Kong Stock Exchange ↔ Insilico Medicine
Hong Kong Stock Exchange ↔ Insilico Medicine
ERGEN INTELLIGENCE
Track Insilico Medicine live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.